Pronutria Biosciences, a clinical stage biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, today announced the successful completion of a $39 million Series C financing led by new investor Fidelity Management & Research Company and joined by founding investor Flagship Ventures, among others.

'We are delighted to welcome Fidelity as a new investor in Pronutria. Fidelity's support, as well as the continued participation of our existing investors, signals a strong belief in our company's revolutionary approach and the vast application of our technology, as well as our ability to execute on an ambitious plan and pipeline due to the highly experienced team we have assembled,' said Robert Connelly, President and Chief Executive Officer at Pronutria. 'We have amassed a significant amount of promising preclinical and clinical data from a pipeline of candidates spanning multiple conditions. With these funds, we are now in a position to aggressively advance multiple programs in areas of high unmet nutritional and medical need.'

Pronutria is at the forefront of developing a novel class of amino acid-based products for patients facing serious conditions who currently have few or no options. Leveraging its advanced knowledge of amino acid imbalances, Pronutria is rapidly advancing research and development programs in several nutritional and therapeutic areas including muscle, metabolic, neurological and liver disorders.

'Pronutria has made impressive strides in building the platform, generating promising human data and assembling a team capable of shaping this exciting, emerging area of medicine,' said Noubar Afeyan, Chairman and Co-founder of Pronutria Biosciences. 'We have long known the fundamental role of amino acids in human health, and continue to gain new insights into the important link between amino acid imbalance and numerous conditions. Pronutria is ideally positioned to turn these insights into new therapies.'

About Pronutria Biosciences

Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated. Pronutria Biosciences is developing first-in-class solutions to these conditions with a focus on amino acid biology. Using insights from a clinically validated body of evidence, we are pioneering new nutritional and therapeutic modalities: amino acid biologics. This novel approach allows us to precisely target biology that was previously inaccessible, providing a unique opportunity to address a variety of serious nutritional and medical conditions, such as muscle, metabolic, neurological, liver disorders and inborn errors of metabolism. Founded by Flagship VentureLabs, privately-held Pronutria Biosciences is based in Cambridge MA. For more information, please visit www.pronutriabio.com.